Kaposi's Sarcoma Associated-Herpes Virus (KSHV) Seroprevalence in Pregnant Women in South Africa.
BACKGROUND
Factors previously associated with Kaposi's sarcoma-associated herpesvirus (KSHV) transmission in Africa include sexual, familial, and proximity to river water. We measured the seroprevalence of KSHV in relation to HIV, syphilis, and demographic factors among pregnant women attending public antenatal clinics in the Gauteng province of South Africa.


METHODS
We tested for antibodies to KSHV lytic K8.1 and latent Orf73 antigens in 1740 pregnant women attending antenatal clinics who contributed blood to the "National HIV and Syphilis Sero-Prevalence Survey - South Africa, 2001". Information on HIV and syphilis serology, age, education, residential area, gravidity, and parity was anonymously linked to evaluate risk factors for KSHV seropositivity. Clinics were grouped by municipality regions and their proximity to the two main river catchments defined.


RESULTS
KSHV seropositivity (reactive to either lytic K8.1 and latent Orf73) was nearly twice that of HIV (44.6% vs. 23.1%). HIV and syphilis seropositivity was 12.7% and 14.9% in women without KSHV, and 36.1% and 19.9% respectively in those with KSHV. Women who are KSHV seropositive were 4 times more likely to be HIV positive than those who were KSHV seronegative (AOR 4.1 95%CI: 3.4 - 5.7). Although, women with HIV infection were more likely to be syphilis seropositive (AOR 1.8 95%CI: 1.3 - 2.4), no association between KSHV and syphilis seropositivity was observed. Those with higher levels of education had lower levels of KSHV seropositivity compared to those with lower education levels. KSHV seropositivity showed a heterogeneous pattern of prevalence in some localities.


CONCLUSIONS
The association between KSHV and HIV seropositivity and a lack of common association with syphilis, suggests that KSHV transmission may involve geographical and cultural factors other than sexual transmission.
Malope-Kgokong
Babatyi I
BI
Viral Oncology Section, AIDS and Cancer Virus Program, SAIC-Frederick, NCI-Frederick, Frederick MD, USA. Mhairi.Maskew@righttocare.org.
Macphail
Patrick
P
Mbisa
Georgina
G
Ratshikhopha
Edith
E
Maskew
Mhairi
M
Stein
Lara
L
Sitas
Freddy
F
Whitby
Denise
D
J Infect Dis. 2004 Oct 15;190(8):1382-6
15378429
Lancet. 1995 Sep 23;346(8978):799-802
7674745
J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):474-9
15764964
J Med Virol. 2005 Jan;75(1):93-100
15543582
Blood. 1995 Aug 15;86(4):1276-80
7632932
J Med Virol. 2005 Aug;76(4):571-5
15977229
J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):206-10
12794556
Sex Transm Dis. 2003 Sep;30(9):713-8
12972795
J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):351-5
17195763
Epidemiol Infect. 2004 Dec;132(6):1191-7
15635980
J Infect Dis. 2004 Sep 15;190(6):1068-75
15319855
Am J Epidemiol. 2008 Aug 1;168(3):311-20
18515794
J Immunol Methods. 2010 Apr 30;356(1-2):39-46
20211626
BMC Public Health. 2007 Jul 18;7:160
17640354
J Infect Dis. 2003 Feb 15;187(4):559-68
12599072
J Infect Dis. 2007 Sep 15;196(6):844-52
17703414
J Infect Dis. 2004 Jul 1;190(1):199-200; author reply 200-1
15195261
Int J Cancer. 2008 May 15;122(10):2260-5
18241034
AIDS. 2008 Feb 19;22(4):519-26
18301065
Sex Transm Dis. 2001 Feb;28(2):77-81
11234789
J Natl Cancer Inst. 1998 Mar 4;90(5):395-7
9498490
Int J Cancer. 2000 Nov 1;88(3):489-92
11054682
Int J Cancer. 2007 Jan 15;120(2):321-8
17066452
N Engl J Med. 1995 May 4;332(18):1186-91
7700311
J Infect Dis. 2009 May 15;199(10):1449-56
19351262
BMC Infect Dis. 2008 Aug 18;8:111
18706107
Int J Cancer. 2001 Jun 1;92(5):622-7
11340563
J Infect Dis. 1999 Sep;180(3):600-6
10438345
S Afr Med J. 2006 Jun;96(6):538-43
16841139
Br J Cancer. 2000 Feb;82(3):702-4
10682685
Science. 1994 Dec 16;266(5192):1865-9
7997879